@article{7a6cb9e045de40039623bb22873e419a,
title = "Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives",
abstract = "Background: An elevated prevalence of Type 2 diabetes (T2D) has been observed in people with psychotic disorders and their relatives compared to the general population. It is not known whether this population also has increased genetic risk for T2D. Methods: Subjects included probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder, their first-degree relatives without psychotic disorders, and healthy controls, who participated in the Bipolar Schizophrenia Network for Intermediate Phenotypes study. We constructed sets of polygenic risk scores for T2D (PGRST2D) and schizophrenia (PGRSSCHIZ) using publicly available data from genome-wide association studies. We then explored the correlation of PGRST2D with psychiatric proband or relative status, and with self-reported diabetes. Caucasians and African-Americans were analyzed separately. We also evaluated correlations between PGRSSCHIZ and diabetes mellitus among Caucasian probands and their relatives. Results: In Caucasians, PGRST2D was correlated with self-reported diabetes mellitus within probands, but was not correlated with proband or relative status in the whole sample. In African-Americans, a PGRST2D based on selected risk alleles for T2D in this population did not correlate with proband or relative status. PGRSSCHIZ was not correlated with self-reported diabetes within Caucasian probands. Conclusion: Differences in polygenic risk for T2D do not explain the increased prevalence of diabetes mellitus observed in psychosis probands and their relatives.",
keywords = "Bipolar, Diabetes, Genetic, Polygenic, Psychosis, Schizophrenia",
author = "Padmanabhan, {Jaya L.} and Pranav Nanda and Neeraj Tandon and Mothi, {Suraj S.} and Nicolas Bolo and Steven McCarroll and Clementz, {Brett A.} and Gershon, {Elliot S.} and Pearlson, {Godfrey D.} and Sweeney, {John A.} and Tamminga, {Carol A.} and Keshavan, {Matcheri S.}",
note = "Funding Information: This work was supported in part by the National Institute for Mental Health (NIMH) grants MH078113 , MH077945 , MH077852 , MH077851 , MH077862 , MH072767 , and MH083888 . Dr. Padmanabhan received support from the Janssen Academic Research Mentorship program. Funding Information: There are no conflicts of interest. However, we would like to report the following disclosures: Dr. Padmanabhan has received support from the Janssen Academic Research Mentorship program. Dr. Keshavan has received research support from Sunovion and GlaxoSmithKline. Dr. Pearlson has served on an advisory panel for Bristol-Myers Squibb. Dr. Sweeney has been on advisory boards for Bristol-Myers Squibb, Eli Lilly, Pfizer, Roche, and Takeda and has received grant support from Janssen. Dr. Tamminga has the following disclosures to make: Intracellular Therapies (ITI, Inc)—Advisory Board, drug development; PureTech Ventures—Ad Hoc Consultant; Eli Lilly Pharmaceuticals—Ad Hoc Consultant; Sunovion—Ad Hoc Consultant; Astellas—Ad Hoc Consultant; Cypress Bioscience—Ad Hoc Consultant; Merck—Ad Hoc Consultant; International Congress on Schizophrenia Research—Organizer, unpaid volunteer; National Alliance on Mental Illness—Council Member, unpaid volunteer; American Psychiatric Association—Deputy Editor. The other authors report no disclosures. Funding Information: We would like to acknowledge Dr. Gunvant Thaker for his contributions to the BSNIP Consortium. Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd.",
year = "2016",
month = jun,
day = "1",
doi = "10.1016/j.jpsychires.2016.02.015",
language = "English (US)",
volume = "77",
pages = "52--58",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
}